SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Requiring Stater Month/Day/Yea	ment	3. Issuer Name <b>and</b> Ticker or Trading Symbol BIOGEN IDEC INC. [BIIB]				
		4. Relationship of Reporting Perso (Check all applicable) Director	( )	(Mo		ate of Original Filed
C CENTER Director X Officer (give title below)		Other (specify below)		6. Individual or Joint/Group Filing (Check Applicable Line)		
		EVP Corporate & Busi	ness Devel		Form filed b	y One Reporting Person
						y More than One erson
Table I - Non-Derivative Securities Beneficially Owned						
1. Title of Security (Instr. 4)		Beneficially Owned (Instr. 4)			4. Nature of Indirect Beneficial Ownership (Instr. 5)	
Common Stock		10,605	D			
Table II - Derivative Securities Beneficially Owned       (e.g., puts, calls, warrants, options, convertible securities)						
2. Date Exercisable and Expiration Date (Month/Day/Year)				or Exercise	se Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable	Expiration Date	n Title	Amount or Number of Shares	Derivative Security	or Indirect (I) (Instr. 5)	
(1)	03/02/2019	Common Stock	28,210	44	D	
	Table II - Nor Table II - Nor 2. Date Exercisable Date Exercisable	Table I - Non-Derivative     Table II - Derivative     g., puts, calls, warra     2. Date Exercisable and Expiration Date (Month/Day/Year)     Date Exercisable and Expiration Date     Date Exercisable and Expiration Date	Requiring Statement (Month/Day/Year)   BIOGEN IDEC INC.     04/13/2009   4. Relationship of Reporting Perso (Check all applicable)     Director   X     VICCERCIPTION   Officer (give title below)     EVP Corporate & Busi     Fable I - Non-Derivative Securities Beneficially     2. Amount of Securities Beneficially Owned (Instr. 4)     10,605     Table II - Derivative Securities Beneficially Owned (Instr. 4)     2. Date Exercisable and Expiration Date (Month/Day/Year)   3. Title and Amount of Security Underlying Derivative Security     Date Exercisable   Expiration Date   Title	Requiring Statement (Month/Day/Year)   BIOGEN IDEC INC.   [BIIB]     04/13/2009   4. Relationship of Reporting Person(s) to Issuer (Check all applicable)     Director   10% Owner X     Officer (give title below)   Other (spectrow)     EVP Corporate & Business Devel     Image: Statement (Instr. 4)   3. Ownership Form: Director     Image: Statement (Instr. 4)   3. Ownership Form: Director     Image: Statement (Instr. 4)   3. Ownership Form: Director     Image: Statement (Instr. 4)   10,605     Image: Statement (Instr. 4)   Detent (Instr. 4)     Image: Statement (Instr. 4)   Image: Statement (Instr. 4)  <	Requiring Statement (Month/Day/Year)   BIOGEN IDEC INC.   BIIB     04/13/2009   4. Relationship of Reporting Person(s) to Issuer (Check all applicable)   5. If (Month/Day/Year)     04/13/2009   4. Relationship of Reporting Person(s) to Issuer (Check all applicable)   5. If (Month/Day/Year)     0   0   0     X   Officer (give title below)   0     EVP Corporate & Business Devel   3     Fable I - Non-Derivative Securities Beneficially Owned (Instr. 4)   3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)   4. Na (Instr Or     Table II - Derivative Securities Beneficially Owned g., puts, calls, warrants, options, convertible securities (Month/Day/Year)   3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)   4. Conversion or Exercisable and Expiration Date (Month/Day/Year)     Date   Expiration Date   3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)   4. Conversion or Exercisable of Shares	Requiring Statement (Month/Day/Year)   BIOGEN IDEC INC. [BIIB]     04/13/2009   4. Relationship of Reporting Person(s) to Issuer (Check all applicable)   5. If Amendment, Day (Month/Day/Year)     0   Officer (give title below)   Other (specify below)   6. Individual or Joint Applicable Line)     X   Officer (give title below)   Other (specify below)   6. Individual or Joint Applicable Line)     Table I - Non-Derivative Securities Beneficially Owned   3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)   4. Nature of Indirect (Instr. 5)     10,605   D   0     Table II - Derivative Securities Beneficially Owned g., puts, calls, warrants, options, convertible securities (Month/Day/Year)   3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)   4. Conversion or Exercise Price of Derivative Shares   5. Ownership Form: Date     Date   Expiration Date   3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)   4. Conversion or Exercise Price of Derivative Shares   5. Ownership Form: Date

Explanation of Responses:

1. The stock options become exercisable in four (4) equal annual installments commencing one year after the grant date of 03/02/09.

/s/ Aras Lapinskas, Attorney in fact for Michael E. Lytton 04/22/2009

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

Know all by these presents, that the undersigned hereby makes, constitutes and appoints Susan H. Alexander, Aras Lapinskas, Robert A. Licht, Robin A. Walker and Marcia J. Gookin as the undersigned's true and lawful attorney-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to:

(1) prepare, execute in the undersigned?s name and on the undersigned?s behalf, and submit to the U.S. Securities and Exchange Commission (the ?SEC?) a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC;

(2) prepare, execute, acknowledge, deliver and file Forms 3, 4, and 5 (including any amendments thereto) with respect to the securities of Biogen Idec Inc., a Delaware corporation (the "Company"), with the United States Securities and Exchange Commission, any national securities exchanges and the Company, as considered necessary or advisable under Section 16(a) of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from time to time (the "Exchange Act");

(3) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to the undersigned and approves and ratifies any such release of information; and

(4) perform any and all other acts which in the discretion of such attorney-in-fact are necessary or desirable for and on behalf of the undersigned in connection with the foregoing.

The undersigned acknowledges that:

(1) this Limited Power of Attorney authorizes, but does not require, such attorney-in-fact to act in their discretion on information provided to such attorney-in-fact without independent verification of such information;

(2) any documents prepared and/or executed by such attorney-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney will be in such form and will contain such information and disclosure as such attorney-in-fact, in his or her discretion, deems necessary or desirable;

(3) neither the Company nor such attorney-in-fact assumes (i) any liability for the undersigned's responsibility to comply with the requirement of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and

(4) this Limited Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under the Exchange Act, including without limitation the reporting requirements under Section 16 of the Exchange Act.

The undersigned hereby gives and grants the foregoing attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing matters as fully to all intents and purposes as the undersigned might or could do if present, hereby ratifying all that such attorney-in-fact of, for and on behalf of the undersigned, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney.

This Limited Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to such attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney to be executed as of this 13th day of April, 2009.

> \_/s/ Michael E. Lytton\_\_\_\_ Signature

Name: Michael E. Lytton